Michaela Medova

Dr. Michaela Medova

Department for BioMedical Research (DBMR), Universitat Bern, Bern, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CMCarmen Muñoz-Maldonado
Carmen Muñoz-Maldonado
YZYitzhak Zimmer
Yitzhak Zimmer
MMMichaela Medova
Michaela Medova
In human cells, three closely related RAS genes, termed HRAS, KRAS, and NRAS, encode four highly homologous proteins. RAS proteins are small GTPases involved in a broad spectrum of key molecular and cellular activities, including proliferation and survival among others. Gain-of-function missense mutations, mostly located at codons 12, 13, and 61, constitutively activate RAS proteins and can be detected in various types of human cancers. KRAS is the most frequently mutated, followed by NRAS and HRAS. However, each isoform exhibits distinctive mutation frequency at each codon, supporting the hypothesis that different RAS mutants may lead to distinct biologic manifestations. This review is focused on the differences in signaling and phenotype, as well as on transcriptomics, proteomics, and metabolomics profiles related to individual RAS-mutated variants. Additionally, association of these mutants with particular targeted outcomes and rare mutations at additional RAS codons are discussed.

3 October 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JGJacopo Gavini
Jacopo Gavini
NDNoëlle Dommann
Noëlle Dommann
MJManuel O. Jakob
Manuel O. Jakob
AKAdrian Keogh
Adrian Keogh
LBLaure C. Bouchez
Laure C. Bouchez
VBVanessa Banz
Vanessa Banz
Lysosomal sequestration of anti-cancer compounds reduces drug availability at intracellular target sites, thereby limiting drug-sensitivity and inducing chemoresistance. For hepatocellular carcinoma (HCC), sorafenib (SF) is the first line systemic treatment, as well as a simultaneous activator of autophagy-induced drug resistance. The purpose of this study is to elucidate how combination therapy with the FDA-approved photosensitizer verteporfin (VP) can potentiate the antitumor effect of SF, overcoming its acquired resistance mechanisms. HCC cell lines and patient-derived in vitro and in vivo preclinical models were used to identify the molecular mechanism of action of VP alone and in combination with SF. We demonstrate that SF is lysosomotropic and increases the total number of lysosomes in HCC cells and patient-derived xenograft model. Contrary to the effect on lysosomal stability by SF, VP is not only sequestered in lysosomes, but induces lysosomal pH alkalinization, lysosomal membrane permeabilization (LMP) and tumor-selective proteotoxicity. In combination, VP-induced LMP potentiates the antitumor effect of SF, further decreasing tumor proliferation and progression in HCC cell lines and patient-derived samples in vitro and in vivo. Our data suggest that combination of lysosome-targeting compounds, such as VP, in combination with already approved chemotherapeutic agents could open a new avenue to overcome chemo-insensitivity caused by passive lysosomal sequestration of anti-cancer drugs in the context of HCC.

7 February 2020 in Oncogene
Verified
Journal Article
Closed access
PDF file
JKJonas P. Koch
Jonas P. Koch
DADaniel M. Aebersold
Daniel M. Aebersold
YZYitzhak Zimmer
Yitzhak Zimmer
MMMichaela Medova
Michaela Medova

11 March 2011 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MMMichaela Medova
Michaela Medova
DADaniel M Aebersold
Daniel M Aebersold
ZYZimmer Yitzhak
Zimmer Yitzhak
Abnormal activation of cellular DNA repair pathways by deregulated signaling of receptor tyrosine kinase systems has broad implications for both cancer biology and treatment. Recent studies suggest a potential link between DNA repair and aberrant activation of the hepatocyte growth factor receptor Mesenchymal‐Epithelial Transition (MET), an oncogene that is overexpressed in numerous types of human tumors and considered a prime target in clinical oncology. Using the homologous recombination (HR) direct‐repeat direct‐repeat green fluorescent protein ((DR)‐GFP) system, we show that MET inhibition in tumor cells with deregulated MET activity by the small molecule PHA665752 significantly impairs in a dose‐dependent manner HR. Using cells that express MET‐mutated variants that respond differentially to PHA665752, we confirm that the observed HR inhibition is indeed MET‐dependent. Furthermore, our data also suggest that decline in HR‐dependent DNA repair activity is not a secondary effect due to cell cycle alterations caused by PHA665752. Mechanistically, we show that MET inhibition affects the formation of the RAD51‐BRCA2 complex, which is crucial for error‐free HR repair of double strand DNA lesions, presumably via downregulation and impaired translocation of RAD51 into the nucleus. Taken together, these findings assist to further support the role of MET in the cellular DNA damage response and highlight the potential future benefit of MET inhibitors for the sensitization of tumor cells to DNA damaging agents.

1 October 2009 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
VBVanessa M. Banz
Vanessa M. Banz
MMMichaela Medova
Michaela Medova
AKAdrian Keogh
Adrian Keogh
CFCynthia Furer
Cynthia Furer
YZYitzhak Zimmer
Yitzhak Zimmer
DSDeborah Stroka
Deborah Stroka

1 October 2010 in Genes & Cancer
Verified
Journal Article
Closed access
MMMichaela Medova
Michaela Medova
DAD. M. Aebersold
D. M. Aebersold
WBW. Blank-Liss
W. Blank-Liss
BSB. Streit
B. Streit
MMMatúš Medo
Matúš Medo
ZYZimmer Yitzhak
Zimmer Yitzhak
While recent studies implicate that signaling through the receptor tyrosine kinase MET protects cancer cells from DNA damage, molecular events linking MET to the DNA damage response machinery are largely unknown. Here, we studied the impact of MET inhibition by the small molecule PHA665752 on cytotoxicity induced by DNA-damaging agents. We demonstrate that PHA665752 reduces clonogenic survival of tumor cells with MET overexpression when combined with ionizing radiation and synergistically cooperates with ionizing radiation or adriamycin to induce apoptosis. In search of mechanisms underlying the observed synergism, we show that PHA665752 alone considerably increases γH2AX levels, indicating the accumulation of double-strand DNA breaks. In addition, PHA665752 treatment results in sustained high levels of γH2AX and phosphorylated ATM postirradiation, strengthening the assumption that MET inhibition attenuates postdamage DNA repair. PHA665752, alone or in combination with irradiation, leads also to a massive increase of γH2AX tyrosine phosphorylation and its subsequent interaction with the proapoptotic kinase JNK1. Finally, MET inhibition reduces activation of ATR, CHK1, and CDC25B and abrogates an associated DNA damage-induced S phase arrest. This indicates that MET inhibition compromises a critical damage-dependent checkpoint that may enable DNA-damaged cells to exit cell cycle arrest before repair is completed.